Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis.
Authors
- Yan Xu (ORCID: https://orcid.org/0009-0000-4999-5043)
- Hui Li (ORCID: https://orcid.org/0009-0002-1432-4148)
- Junchen He (ORCID: https://orcid.org/0009-0001-7838-8514)
- Dongyun Lei (ORCID: https://orcid.org/0000-0002-6741-959X)
- Litao Zhang
- Qunyan Li
- Zuotao Zhao
- Tao Guo
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1639049
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00